Tags

Type your tag names separated by a space and hit enter

Viral respiratory infections due to rhinoviruses: current knowledge, new developments.
Am J Ther. 2003 May-Jun; 10(3):193-202.AJ

Abstract

Viral respiratory infections (VRIs) are among the most common reasons for which primary care providers are consulted. VRIs due to rhinoviruses-the most commonly implicated etiologic agent-constitute a syndrome characterized by signs and symptoms of a cold. Rhinoviruses have been implicated in respiratory tract illnesses such as sinusitis and otitis media, as well as lower respiratory complications in high-risk populations. Most patients treat VRI with over-the-counter remedies that have been demonstrated to produce marginal clinical benefits. The development of novel antiviral agents has intensified interest in VRIs. Pleconaril, a capsid-function inhibitor currently under FDA review, has been shown in clinical trials to reduce the duration and severity of rhinovirus VRIs. By targeting the cause of illness, antiviral agents represent an opportunity to reduce the substantial clinical burden of VRI. Furthermore, effective therapies can potentially reduce inappropriate antibiotic use for viral infections.

Authors+Show Affiliations

Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, MI, USA. amfen@med.umich.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12756426

Citation

Fendrick, A Mark. "Viral Respiratory Infections Due to Rhinoviruses: Current Knowledge, New Developments." American Journal of Therapeutics, vol. 10, no. 3, 2003, pp. 193-202.
Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003;10(3):193-202.
Fendrick, A. M. (2003). Viral respiratory infections due to rhinoviruses: current knowledge, new developments. American Journal of Therapeutics, 10(3), 193-202.
Fendrick AM. Viral Respiratory Infections Due to Rhinoviruses: Current Knowledge, New Developments. Am J Ther. 2003 May-Jun;10(3):193-202. PubMed PMID: 12756426.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Viral respiratory infections due to rhinoviruses: current knowledge, new developments. A1 - Fendrick,A Mark, PY - 2003/5/21/pubmed PY - 2003/10/11/medline PY - 2003/5/21/entrez SP - 193 EP - 202 JF - American journal of therapeutics JO - Am J Ther VL - 10 IS - 3 N2 - Viral respiratory infections (VRIs) are among the most common reasons for which primary care providers are consulted. VRIs due to rhinoviruses-the most commonly implicated etiologic agent-constitute a syndrome characterized by signs and symptoms of a cold. Rhinoviruses have been implicated in respiratory tract illnesses such as sinusitis and otitis media, as well as lower respiratory complications in high-risk populations. Most patients treat VRI with over-the-counter remedies that have been demonstrated to produce marginal clinical benefits. The development of novel antiviral agents has intensified interest in VRIs. Pleconaril, a capsid-function inhibitor currently under FDA review, has been shown in clinical trials to reduce the duration and severity of rhinovirus VRIs. By targeting the cause of illness, antiviral agents represent an opportunity to reduce the substantial clinical burden of VRI. Furthermore, effective therapies can potentially reduce inappropriate antibiotic use for viral infections. SN - 1075-2765 UR - https://www.unboundmedicine.com/medline/citation/12756426/Viral_respiratory_infections_due_to_rhinoviruses:_current_knowledge_new_developments_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=12756426.ui DB - PRIME DP - Unbound Medicine ER -